All In Biotech

Drug Trial Radar · NCT00424190

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 698 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

698

Actual

Start

Feb 2007

Primary completion

Nov 2007

Study completion Nov 2007

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Conditions

  • Bacterial Infections

Interventions

  • IV Vancomycin plus IV AztreonamDrug

    vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

  • CeftarolineDrug

    600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate at Test of Cure (TOC) (MITT Population)Time frame: 8-15 days after the end of treatment
  2. Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) PopulationTime frame: 8-15 days after last dose of study drug

Locations

52 sites in 11 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Dothan, Alabama

  • Investigational Site

    Long Beach, California

  • Investigational Site

    Los Angeles, California

  • Investigational Site

    Sacramento, California

  • Investigational Site

    Sacramento, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    San Francisco, California

  • Investigational Site

    Torrance, California

  • Investigational Site

    Savannah, Georgia

  • Investigational Site

    Naperville, Illinois

  • Investigational Site

    Indianapolis, Indiana

  • Investigational Site

    Shreveport, Louisiana

  • Investigational Site

    Columbus, Ohio

  • Investigational Site

    Landsdale, Pennsylvania

  • Investigational Site

    Tacoma, Washington

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Invetigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Córdoba, Argentina

  • Invetigational Site

    Córdoba, Argentina

  • Investigational Site

    Entre Ríos, Argentina

  • Investigational Site

    Santa Fe, Argentina

  • Investigational Site

    Curiuba-Parans, Brazil

  • Investigational Site

    São Paulo, Brazil

  • Investigational Site

    Santiago, Chile

  • Investigational Site

    Viña del Mar, Chile

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Bochum, Germany

  • Investigational Site

    Hanau, Germany

  • Investigational Site

    Plauen, Germany

  • Investigational Site

    Quedlinburg, Germany

  • Investigational Site

    Chihuahua City, Mexico

  • Invetigational Site

    Lima, Peru

  • Investigational Site

    Bytom, Poland

  • Investigational Site

    Krakow, Poland

  • Investigational Site

    Lublin, Poland

  • Investigational Site

    Sosnowiec, Poland

  • Investigational Site

    Todz, Poland

  • Investigational Site

    Bucharest, Romania

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.